steven tepper pharmaceut biom analyst
updat cut guidanc attest
weak core busi lower pt
report revenu touch lower
consensu estim adjust ep came higher market
estim result mainli lower rate
manag made cut guidanc despit result lower
ep rang bring total reduct sinc
begin year also made reduct revenu
guidanc altogeth sinc begin year
guidanc cut suggest compani number also
estim weak due mainli persist weak gener
busi us heavi eros margin over-the-counter product
region hand improv intern
busi partial off-set disappoint result us
overal yet anoth weak quarter attest
compani increas lack focu revenu net
consum healthcar america chca revenu unchang yoy
oper margin slump weak
result mainli weak pet healthcar busi higher input cost
oper ineffici factor affect result view
profoundli disappoint perform gener nexium launch
exactli year ago rel small number new launch
consum healthcar chci revenu lower
yoy unchang translat local currenc oper margin improv
vs new product line greater oper effici
rx revenu fell oper margin narrow declin
weak due mainli challeng market dynam result
lower sale volum number product price eros less profit
product mix state earn releas declin also due
larg degre increas spend
one time expens made impair charg intang
asset goodwil write affect cash flow attest
weak compani core busi chca rx
announc new share buy-back program time limit see
repurchas worth share perspect impli
compani eschew major expans busi would rather give
money back investor instead
new ceo murray kessler present vision call greater
focu compani core busi view make consum
product compani time strategi underpin self-car rather
healthcar shift strategi claim kessler give compani access vast
new opportun healthcar market
set goal fulli separ rx busi task
execut vice-president sharon kochan overse process fruition
either sell spin separ busi kessler
think rx busi good profit nonetheless feel distract
core consum busi
henceforth focu organ growth leverag compani strength
consum healthcar product compani expect make
acquisit forese futur consid buy bolt busi
situat moment accord kessler abysm
compani said gotten track recent year lose focu
core busi sizabl part competit edg enjoy us
consum product busi kessler also flag steadi decreas rx
over-the-counter product switch situat coupl increas price pressur
render current product pipelin insuffici
kessler stress open remark still except
strong point leverag work turn around compani
fortun begin claim current difficulti result distract
shift leadership rapidli chang extern environ properli
valuat outlook
maintain market perform rate lower price target
price base multipl eps mean
still fairli valu
still think valuat reflect compani uniqu leadership market
one hand take account absenc clear growth driver
year uncertainti surround outcom compani state goal
divest rx gener busi
new ceo intend steer compani focu back core consum product
busi strategi clearli emerg refer call self-
care rather healthcar compani understand stage exactli
transform entail await color manag
-for qualifi client
